Propensity Score Matching Analysis for Alcohol-Related Liver Disease

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL Health Science Reports Pub Date : 2025-01-12 DOI:10.1002/hsr2.70257
Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang
{"title":"Propensity Score Matching Analysis for Alcohol-Related Liver Disease","authors":"Fangfang Duan,&nbsp;Shanshan Song,&nbsp;Hang Zhai,&nbsp;Yazhi Wang,&nbsp;Jun Cheng,&nbsp;Song Yang","doi":"10.1002/hsr2.70257","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol-related liver disease (ARLD).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Patients with ARLD and those with ARLD co-morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5-year survival rates compared to the ARLD group (51.3% vs. 70.1%, <i>p</i> &lt; 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, <i>p</i> = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver-specific mortality after matching (32.6% vs. 6.2%, <i>p</i> = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post-matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, <i>p</i> = 0.170).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Co-morbidity with CHB in ARLD patients elevates the risk of liver-related mortality.</p>\n </section>\n </div>","PeriodicalId":36518,"journal":{"name":"Health Science Reports","volume":"8 1","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725528/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Science Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol-related liver disease (ARLD).

Methods

Patients with ARLD and those with ARLD co-morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups.

Results

Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5-year survival rates compared to the ARLD group (51.3% vs. 70.1%, p < 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, p = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver-specific mortality after matching (32.6% vs. 6.2%, p = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post-matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, p = 0.170).

Conclusion

Co-morbidity with CHB in ARLD patients elevates the risk of liver-related mortality.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
酒精相关性肝病的倾向评分匹配分析
目的:本研究旨在探讨慢性乙型肝炎(CHB)合并症对酒精相关性肝病(ARLD)患者生存率和肝癌发病率的影响。方法:将ARLD合并慢性乙型肝炎患者和ARLD合并慢性乙型肝炎患者纳入本研究,分别分为ARLD组和ARLD + HBV组。然后采用倾向评分匹配(PSM)来比较两组之间的生存率和肝癌发展情况。结果:404例患者中,ARLD组254例,ARLD + HBV组150例。倾向评分匹配后,每组67例。最初,与ARLD组相比,ARLD + HBV组的5年生存率较低(51.3%对70.1%,p p = 0.390)。值得注意的是,ARLD + HBV组匹配后肝脏特异性死亡率发生率更高(32.6% vs. 6.2%, p = 0.018)。此外,虽然ARLD + HBV组患者配型后发生肝癌的比例较高,但与ARLD组相比差异无统计学意义(15.7% vs. 9.8%, p = 0.170)。结论:ARLD患者合并CHB可增加肝脏相关死亡风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Health Science Reports
Health Science Reports Medicine-Medicine (all)
CiteScore
1.80
自引率
0.00%
发文量
458
审稿时长
20 weeks
期刊最新文献
Assessing the Effectiveness of the Human Immunodeficiency Virus Point-of-Care Proficiency Testing Scheme: Analysis of the Data From 2021 to 2022 in South Africa. Psychological Inclinations and Practical Utility of ChatGPT Among Undergraduate Dental Students at a Dental School in Karachi: A Cross-Sectional Observational Study. The Four-Square Step Test With and Without Dual Tasks Among Older Adults With and Without a Fall History: A Retrospective Cohort Study. Association of Frailty and Perioperative Outcomes Across Surgical Specialties Between 2016 and 2018 Using the National Inpatient Sample Database: A Retrospective Cohort Study. An Empty Scoping Review on the Financing of Necrotizing Periodontal Disease Prevention and Control in Africa: Implications for Global Oral Health Research, Policy, and Practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1